The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

Early Puberty Clinical Trial

Official title:
A Randomized, Single-blinded, Parallel Design Phase I Clinical Trial to Investigate the Safety and Pharmacokinetics/Pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. After Subcutaneous Injection in Postmenopausal Female

Status Not yet recruiting

Clinical Trial Summary

A randomized, single-blinded, parallel design phase I clinical trial to investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. after subcutaneous injection in postmenopausal female

Clinical Trial Description

To investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. 3.75 mg after subcutaneous injection in postmenopausal female ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04840745
Study type	Interventional
Source	Chong Kun Dang Pharmaceutical
Contact	Min Soo Park, Ph.D
Phone	82-2-2228-0401
Email	minspark@yuhs.ac
Status	Not yet recruiting
Phase	Phase 1
Start date	April 2021
Completion date	November 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04317014` - the Association Between Obesity and Early Puberty
Completed	`NCT01679925` - Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years	N/A
Recruiting	`NCT05338411` - Effect of Exogenous Growth Hormone on Ocular Findings